title: The role of ifosfamide in the treatment of sarcomas.
abstract: The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas. In advanced soft tissue sarcomas, doxorubicin and ifosfamide are the most active single agents. Their combination results in response rates of 34% to 41% in various trials. In advanced osteosarcoma and Ewing's sarcoma, ifosfamide also is active. In Ewing's sarcoma, the above combination with etoposide has resulted in high response rates.
authors.affiliation: Department of Oncology, Antwerp University Hospital, Edegem, Belgium.
authors.forename: L Y
authors.initials: LY
authors.lastname: Dirix
authors.forename: A T
authors.initials: AT
authors.lastname: Van Oosterom
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy*; D012512:Sarcoma, Ewing / Q000188:drug therapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy
chemical_list: D007069:Ifosfamide